Cargando…
Gene Therapy for Hemophilia: Facts and Quandaries in the 21st Century
Therapy for hemophilia has evolved in the last 40 years from plasma-based concentrates to recombinant proteins and, more recently, to non-factor therapeutics. Along this same timeline, research in adeno-associated viral (AAV) based gene therapy vectors has provided the framework for early phase clin...
Autores principales: | Arruda, Valder R., Doshi, Bhavya S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485465/ https://www.ncbi.nlm.nih.gov/pubmed/32952980 http://dx.doi.org/10.4084/MJHID.2020.069 |
Ejemplares similares
-
Emerging therapies for hemophilia: controversies and unanswered questions
por: Arruda, Valder R., et al.
Publicado: (2018) -
Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy
por: Samelson-Jones, Benjamin J., et al.
Publicado: (2018) -
B cell–activating factor modulates the factor VIII immune response in hemophilia A
por: Doshi, Bhavya S., et al.
Publicado: (2021) -
Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A
por: Samelson-Jones, Benjamin J., et al.
Publicado: (2020) -
Official statistics 4.0: verified facts for people in the 21st century
por: Radermacher, Walter J
Publicado: (2020)